|
Roche Media News
|
Media Releases
|
|
-
Roche will report new data on important progress for people with advanced cancers at ASCO 2012
Roche today announced that the company will present important new data from studies of several of its cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1 to 5, 2012, in Chicago. At the meeting, data on Roche’s late-stage investigational and approved cancer medicines will be communicated in sessions that include 30 oral presentations.
-
Roche provides update on Phase III study of dalcetrapib
Roche today announced that following the results of the second interim analysis of the dalcetrapib dal-OUTCOMES Phase III trial, the independent Data and Safety Monitoring Board (DSMB) has recommended stopping the trial due to a lack of clinically meaningful efficacy. The dal-OUTCOMES trial evaluated the efficacy and safety profile of dalcetrapib when added to existing standard of care in patients with stable coronary heart disease (CHD) following an acute coronary syndrome (ACS). No safety signals relating to the dal-OUTCOMES trial were reported from the DSMB.
-
Roche reports positive study of RoACTEMRA given by subcutaneous injection
Roche today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) formulation of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) 162mg weekly compared to 8 mg/kg RoACTEMRA intravenous (IV) formulation every 4 weeks.
-
Roche decides not to extend its tender offer for Illumina, Inc.
Roche released the following statement based on preliminary estimates indicating the re-election of the incumbent directors of Illumina, Inc. (NASDAQ: ILMN) at the Illumina annual meeting
-
Roche on track for full-year targets - good sales growth in first quarter
Group sales rise 2% at CER (-1% in Swiss francs; +1% in US dollars) to 11.0 billion Swiss francs. Excluding Tamiflu, sales growth is 3%.
-
Roche issues statement regarding Illumina offer
Roche released the following statement regarding its pending offer for Illumina, Inc. (NASDAQ: ILMN)
-
Roche sends open letter to Illumina shareholders
Roche today sent an open letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to vote the GOLD proxy card for Roche’s independent director nominees and other proposals at the 2012 Illumina annual meeting to be held on 18 April 2012.
-
Roche disappointed with ISS recommendation
Roche released the following statement in response to a report issued by Institutional Shareholder Services (“ISS”) recommending that shareholders of Illumina, Inc. (NASDAQ: ILMN) vote against the election of Roche’s independent director nominees to Illumina’s Board of Directors
-
Roche sends second letter to Illumina shareholders
Roche (SIX: RO, ROG; OTCQX: RHHBY) today sent a second letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to tender their shares into Roche’s increased offer and vote for Roche’s independent director nominees and other proposals at the 2012 Illumina annual meeting to be held on 18 April 2012.
-
Roche disappointed by Illumina, Inc.'s Board of Directors' rejection
By not engaging with Roche, Illumina reinforces notion of an entrenched Board. Roche released the following statement in response to the announcement by Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has recommended that shareholders not tender their shares to Roche’s increased offer.
|
